Edward Benz

Edward J.
Benz currently works at The Mount Desert Island Biological Laboratory, as Vice Chairman, F-Star Biotechnologische Forschungs- Und Entwicklungsges MBH, as Director, National Institutes of Health, as Executive Director-Cure Sickle Cell Initiative, The Rockefeller University, as Director, Mount Desert Island Hospital, Inc., as Director, Massachusetts Life Sciences Center, as Director from 2011, Candel Therapeutics, Inc., as Independent Director from 2017, F-star Biotechnology Ltd., as Director from 2020, Knowledge to Practice, Inc., as Director from 2015, Renovacor Holdings, Inc., as Director from 2017, Renovacor, Inc., as Independent Director from 2017, CoRegen, Inc., as Director, Riverside Partners LLC, as Advisor, and Dana-Farber, as Trustee.
Dr. Benz also formerly worked at Dana-Farber Cancer Institute, Inc., as President, Chief Executive Officer & Director from 2000 to 2016, Partners Cancercare, as Chief Executive Officer, The Johns Hopkins University School of Medicine, as Chairman-Medicine Department & Professor from 1995 to 2000, Dana-Farber, as Director from 2000 to 2016, F-Star Therapeutics, Inc. (United States), as Director, Xenetic Biosciences, Inc., as Director from 2016 to 2017, F-star Therapeutics, Inc., as Independent Director from 2019 to 2023, Deciphera Pharmaceuticals, Inc., as Independent Director from 2019 to 2024, American Society of Hematology, as President, American Society for Clinical Investigation, as President, Harvard Medical School, as Dean in 2000, Association of American Cancer Institutes, as President, New England Journal of Medicine, as Associate Editor, Friends of The National Institute of Nursing Research, as President, and American Clinical & Climatological Association, as President.
Dr. Benz received his graduate degree from Yale University, undergraduate degree in 1968 from Princeton University, and doctorate degree from Harvard Medical School.